Class Action Lawsuit for Capricor Investors
Levi & Korsinsky, LLP is reaching out to investors of Capricor Therapeutics, Inc. regarding a significant class action securities lawsuit. This action is specifically intended for those who may have suffered losses due to alleged securities fraud.
Understanding the Lawsuit
The class action seeks compensation for Capricor investors who were impacted by events related to the company’s lead cell therapy candidate for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The lawsuit covers a time frame during which investors faced material misinformation regarding the viability and regulatory approval prospects of Capricor's drug, deramiocel.
The Allegations
According to the complaint, Capricor’s executives provided optimistic projections about securing a Biologics License Application (BLA) for deramiocel from the FDA. However, it is alleged that these representations were misleading and did not disclose critical negative information regarding clinical safety and efficacy data from the Phase 2 HOPE-2 trial.
Impact on Investors
After the company announced on July 11 that the FDA issued a Complete Response Letter (CRL), detailing substantial issues with their application, the stock price suffered a notable drop. From a high of $11.40 per share on July 10, it plummeted to $7.64 the next day after the unfavorable announcement.
What Should Affected Investors Do?
If you have experienced losses with Capricor shares during the indicated period, there is a deadline of September 15 to act. Maximize your potential recovery by requesting to be appointed as a lead plaintiff, although doing so is not necessary to gain from the eventual settlement.
No Cost Involved
Participating in this class action comes with no financial burden for class members. It’s an opportunity to reclaim some of the losses incurred during these troubling times in the stock's movements.
Why Choose Levi & Korsinsky?
With a notable history of success in securities cases spanning over two decades, Levi & Korsinsky has recovered significant amounts for harmed shareholders. Their dedicated team comprises experienced professionals who prioritize client needs and navigate the complexities of securities litigation expertly.
Firm Contact Information
For more details and assistance, investors can contact the firm directly. Reach out to Joseph E. Levi or Ed Korsinsky at Levi & Korsinsky, LLP, located at 33 Whitehall Street, 17th Floor, New York, NY 10004.
Frequently Asked Questions
1. What is the Capricor class action lawsuit about?
The lawsuit addresses alleged securities fraud affecting Capricor Therapeutics investors during a specified period.
2. When is the deadline to join the class action?
The deadline is September 15, 2025, to request appointment as lead plaintiff.
3. Do I have to pay to participate in this lawsuit?
No, there are no out-of-pocket costs for class members involved in the lawsuit.
4. How can I contact Levi & Korsinsky for more information?
Investors can reach out via phone at (212) 363-7500 for further inquiries.
5. What is the track record of Levi & Korsinsky?
The firm has a robust history of securing recoveries for shareholders, consistently ranked among the top litigation firms in the United States.
